Advertisement

International Journal of Clinical Pharmacy

, Volume 36, Issue 6, pp 1141–1143 | Cite as

Acute and fatal thrombocytopenic thrombotic purpura after a single dose of pemetrexed

  • Irene Alabiso
  • Chiara BaratelliEmail author
  • Maria Pia Brizzi
  • Raffaella Bitossi
  • Azzurra Ottone
  • Marco Tampellini
Case Report

Abstract

Case Thrombocytopenic thrombotic purpura (TTP), a life-threatening event consisting of disseminated vascular thrombosis, has never been described before as a possible side effect of the anticancer drug pemetrexed. A 70 years old patient affected by a poorly differentiated non small cell lung cancer, subjected to his first pemetrexed administration, developed an acute thrombocytopenic thrombotic purpura, fatal in a few hours. Conclusions Pemetrexed can cause TTP. Clinicians have to be alert for the rapid onset and aggressiveness of this possible side effect. It is difficult to recognise the first signs and symptoms.

Keywords

Non small cell lung cancer Pemetrexed Thrombocytopenic thrombotic purpura 

Notes

Conflicts of interest

None.

Funding

None.

References

  1. 1.
    Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–97.PubMedCrossRefGoogle Scholar
  2. 2.
    Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer. 2004;5(Suppl 2):S51–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Yoshida K, Kurosaka D, Ozawa Y, Yokoyama T, Tajima N. A case of rheumatoid arthritis associated with autoimmune hemolytic anemia due to weekly low-dose methotrexate therapy. Ryumachi. 2000;40(4):693–8.PubMedGoogle Scholar
  6. 6.
    Park GM, Han KS, Chang YH, Kim CH, Lee JC. Immune hemolytic anemia after treatment with pemetrexed for lung cancer. J Thorac Oncol. 2008;3(2):196–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Sun X, Sheng L, Deng Q, Liu P, Lu K. Severe immune haemolytic anemia due to pemetrexed in a patient with non-small cell lung cancer. Pharmacology. 2011;88(5–6):242–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B. Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002;100(2):710–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Alvarez-Larrán A, del Río-Garma J, Pujol M, de la Rubia J, Hernández-Jodra M, Borrell M, et al. Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment. Ann Hematol. 2009;88(10):973–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Kasi PM. Thrombotic thrombocytopenic purpura and gemcitabine. Case Rep Oncol. 2011;4(1):143–8.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  • Irene Alabiso
    • 1
  • Chiara Baratelli
    • 2
    Email author
  • Maria Pia Brizzi
    • 2
  • Raffaella Bitossi
    • 2
  • Azzurra Ottone
    • 2
  • Marco Tampellini
    • 2
  1. 1.Ospedale San Giovanni BoscoTurinItaly
  2. 2.AOU San Luigi GonzagaOrbassanoItaly

Personalised recommendations